HC Wainwright & Co. Downgrades Soleno Therapeutics to Neutral, Lowers Price Target to $53

Soleno Therapeutics Inc

Soleno Therapeutics Inc

SLNO

0.00

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Soleno Therapeutics (NASDAQ: SLNO) from Buy to Neutral and lowers the price target from $100 to $53.